Aminoglycosides;Aminoglucósidos

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 21, Issue 2, 2003, Pages 105-115

  Palomino, Julián ^a   Pachón, Jeronomo ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Aminoglycosides; Antimicrobial treatment; Once daily dosing

Indexed keywords

AMIKACIN; AMINOCYCLITOL; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CALCIUM CHANNEL; CARBAPENEM; CEPHALOSPORIN DERIVATIVE; DIBEKACIN; GENTAMICIN; GLUCONATE CALCIUM; GLYCOPEPTIDE; ISEPAMICIN; KANAMYCIN; MONOBACTAM DERIVATIVE; NETILMICIN; PAROMOMYCIN; PENICILLIN DERIVATIVE; SISOMICIN; STREPTOMYCIN; TOBRAMYCIN;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACILLUS; BREATHING MUSCLE; CHILL; CLINICAL PRACTICE; DRUG EFFICACY; ENTEROBACTER; ESCHERICHIA COLI; FEVER; FLACCID PARALYSIS; GRAM NEGATIVE INFECTION; HUMAN; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPOTENSION; HYPOVOLEMIA; KIDNEY FAILURE; KLEBSIELLA; LIVER DISEASE; MYDRIASIS; NAUSEA; NEPHROTOXICITY; NEUROMUSCULAR BLOCKING; NYSTAGMUS; OTOTOXICITY; POSTANTIBIOTIC EFFECT; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; REVIEW; TACHYCARDIA; URINARY TRACT INFECTION; VERTIGO;

EID: 0037293666     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13042869     Document Type: Review

References (59)

1. Pancoast SJ. Aminoglycoside antibiotics in clinical use. Med Clin North Am 1988;72:581-612.
2. Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. Aminoglycosides: Activity and resistance. Antimicrob Agents Chemother 1999;43:727-37.
3. Lacy MK, Nicolau DP, Nightingale CH, Quintiliani R. The pharmacodynamics of aminoglycosides. Clin Infect Dis 1998;27:23-7.
4. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-12.
5. Gilbert DN. Aminoglycosides. En: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 5th ed. Philadelphia: Churchill Livingstone, 2000; p. 307-36.
6. Edson RS, Terrell CL. The aminoglycosides. Mayo Clinic Proc 1999;74:519-28.
7. Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH. Once-daily dosing of aminoglycosides: Review and recomendations for clinical practice. J Antimicrob Chemother 1997;39:677-86.
8. Urban AW, Craig WA. Daily dosage of aminoglycosides. Curr Clin Top Infect Dis 1999;17:236-55.
9. Fisman DN, Kaye KM. Once-daily dosing of aminoglycoside antibiotics. Infect Dis Clin North Am 2000;14:475-87.
10. Blaser J, Stone BB, Groner MC, Zinner SH. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 1987;31:1054-60.
11. Eliopoulos GM, Moellering RC. Antimicrobial combinations. En: Lorian V, editor. Antibiotics in Laboratory Medicine, 4th ed. Baltimore: Williams & Wilkins, 1996; p. 330-83.
12. National Committee for Clinical Laboratory Standards. 2001. Performance standards for antimicrobial susceptibility testing. Document M100-S11. Wayne: National Committee for Clinical Laboratory Standards, 2001.
13. Recomendaciones del grupo MENSURA para la selección de antimicrobianos en el estudio de la sensibilidad y criterios para la interpretación del entibiograma. Rev Esp Quimioterap 2000;13:73-86.
14. Schmitz FJ, Verhoef J, Fluit AC, and the SENTRY Participants Group. Prevalence of aminoglycoside resistance in 20 european university hospitals participating in the european SENTRY antimicrobial surveillance programme. Eur J Chn Microbiol Infect Dis 1999;18:414-21.
15. Betriu C, Palau L, Gómez M, Sánchez A, Romero J, Picazo JJ. Bacteriemias en un hospital universitario: estudio de los agentes etiológicos y de sus patrones de sensibilidad. Rev Clin Esp 1999;199:503-10.
16. Fernández-Cuenca F, Pascual A, Vila J, Bou G, Cisneros JM, Rodríguez Baño J, et al. Proyecto GEIH-Ab 2001: Sensibilidad de Acinetobacter spp. aislados en hospitales españoles a los antimicrobianos. X Congreso de la Sociedad Española de Enfermedades Infecciosas y Microbiología Cliníca. Sevilla, 17-20 de marzo de 2002. Enferm Infecc Microbiol Clin 2002;20 (Supl 1): 122; resumen 391.
17. Miller GH, Sabatelli FJ, Hare RS, Glupczynski HY, Mackey P, Shales D, et al. The most frequent aminoglycoside resistance mechanisms-changes with time and geographic area: A reflection of aminoglycoside usage patterns? Clin Infect Dis 1997;24 (Suppl 1):S46-S62.
18. Graham JC, Gould FK. Role of aminoglycosides in the treatment of bacterial endocarditis. J Antimicrob Chemother 2002;49:437-44.
19. Hilf M, Yu L, Sharp J, Zuravleff JJ, Korvick JA, Muder RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989;87:540-6.
20. Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson MP, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991;115:585-90.
21. Korvick JA, Bryan CS, Farber B, Beam TR Jr, Schenfeld L, Muder RR, et al. Prospective observational study of Klebsiella bacteremia in 230 patients: Outcome for antibiotic combinations versus monotherapy. Antimicrob Agents Chemother 1992;36:2639-44.
22. Liebovici L, Paul M, Poznanski O, Drucker M, Samra Z, Konigsberger H, et al. Monotherapy versus β-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother 1997;41:1127-33.
23. Bouza E, Muñoz P. Monotherapy versus combination therapy for bacterial infections. Med Clin North Am 2000;84:1357-89.
24. Lynch JP III. Hospital-acquired pneumonia. Risk factors, microbiology, and treatment. Chest 2001;119:373S-384S.
25. Kashuba ADM, Nafziger AN, Drusano GL, Bertino JS Jr. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother 1999;43:623-9.
26. Rozdzinski E, Kern WV, Reichle A, Moritz T, Schmeiser T, Gaus W, et al. Once-daily versus thrice-daily dosing of netilmicin in combination with beta-lactam antibiotics as empirical therapy for febrile neutropenic patients. J Antimicrob Chemother 1993;31:585-98.
27. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993;119:584-93.
28. Ariffin H, Arasu A, Mahfuzah M, Ariffin WA, Chan LL, Lin HP. Single-daily ceftriaxone plus amikacin versus thrice-daily ceftazidime plus amikacin as empirical treatment of febrile neutropenia in children with cancer. J Paediatr Child Health 2001;37:38-43.
29. Del Favero A, Menichetti F, Martino P, Bucaneve G, Micozzi A, Gentile G, et al. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis 2001;33:1295-301.
30. Van der Auwera P, Meunier F, Ibrahim S, Kaufman L, Derde MP, Tulkens PM. Pharmacodynamic parameters and toxicity of netilmicin (6 milligrams/kilogram/day) given once daily or in three divided doses to cancer patients with urinary tract infection. Antimicrob Agents Chemother 1991;35:640-7.
31. Bailey RR, Begg EJ, Smith AH, Robson RA, Lynn KL, Chambers ST, et al. Prospective, randomized, controlled study comparing two dosing regimens of gentamicin/oral ciprofloxacin switch therapy for acute pyelonephritis. Clin Nephrol 1996;46:183-6.
32. Carapetis JR, Jaquiery AL, Buttery JP, Starr M, Cranswick NE, Kohn S, et al. Randomized, controlled trial comparing once daily and three times daily gentamicin in children with urinary tract infections. Pediatr Infect Dis J 2001;20:240-6.
33. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis 1999;29:745-58.
34. Sandberg T, Alestig K, Eilard T, Ek E, Hebelka M, Johansson E, et al. Aminoglycosides do not improve the efficacy of cephalosporins for treatment of acute pyelonephritis in women. Scand J Infect Dis 1997;29:175-9.
35. Tan K, Bunn H. Once daily multiple daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev 2000;4: CD002009.
36. Whitehead A, Conway SP, Etherington C, Caldwell NA, Setchfield N, Bogle S. Once-daily tobramycin in the treatment of adult patients with cystic fibrosis. Eur Respir J 2002;19:303-9.
37. Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 2002;121:55-63.
38. Badía X, Brosa M, Tellado JM. Medicina basada en la evidencia, costes sanitarios y tratamiento de la infeecion intraabdominal. Enferm Infecc Microbiol Clin 1999;17(Supl 2):86-94.
39. Dupont H, Carbon C, Carlet J for The Severe Generalized Peritonitis Group. Monotherapy with broad-spectrum beta-lactam is as effective as its combination with an aminoglucoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial. Antimicrob Agents Chemother 2000;44:2028-33.
40. Holzheimer RG, Dralle H. Antibiotic therapy in intra-abdominal infections - a review on randomised clinical trials. Eur J Med Res 2001;6:277-91.
41. Gross PA, Barrett TL, Dellinger EP, Krause PJ, Martone WJ, McGowan JE, et al. Purpose of quality standars for infectious diseases. Clin Infect Dis 1994;18:421.
42. Lortholary O, Tod M, Cohen Y, Petitjean O. Aminoglycosides. Med Clin North Am 1995;79:761-87.
43. Gilbert DN, Bennett WM. Use of antimicrobial agents in renal failure. Infect Dis Clin North Am 1989;3:517-31.
44. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2184 adult patients. Antimicrob Agents Chemother 1995;39:650-5.
45. Tod MM, Padoin C, Petitjean O. Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: Simple or complex pharmacokinetic methods? Clin Pharmacokinet 2001;40:803-14.
46. Galloe AM, Graudal N, Christensen HR, Kampmann JP. Aminoglycosides: Single or multiple daily dosing? A meta-analysis on efficacy and safety. Eur J Clin Pharmacol 1995;48:39-43.
47. Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med 1996;124:717-25.
48. Barza M, Ionnidis JPA, Cappelleri JC, Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 1996;312:338-45.
49. Munckhof WJ, Grayson ML, Turnidge JD. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother 1996;37:645-63.
50. Freeman CD, Strayer AH. Mega-analysis of meta-analysis: an examination of meta-analysis with an emphasis on once-daily aminoglycoside comparative trials. Pharmacotherapy 1996;16:1093-102.
51. Ferriols-Lisart R, Alós-Almiñana M. Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. Am J Health Syst Pharm 1996;53:1141-50.
52. Hatala R, Dinh T, Cook DJ. Single daily dosing of aminoglycosides in immunocompromised adults: A systematic review. Clin Infect Dis 1997;24:810-5.
53. Bailey TC, Little JR, Littenberg B, Reichley RM, Dunagan WC. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997;24:786-95.
54. Ali MZ, Goetz MB. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997;24:796-809.
55. Bertino JS, Rotschafer JC. Editorial response: Single daily dosing of aminoglycosides - A concept whose time has not yet come. Clin Infect Dis 1997;24:820-3.
56. Maglio D, Nightingale CH, Nicolau DP. Extended interval aminoglycoside dosing: from concept to clinic. Int J Antimicrob Agents 2002;341-8.
57. Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999;43:1549-55.
58. Beauchamp D, Labrecque G. Aminoglycoside nephrotoxicity: do time and frequency of administration matter? Curr Opin Infect Dis 2001;7:401-8.
59. Singer C, Smith C, Krieff D. Once-daily aminoglycoside therapy: potencial ototoxicity. Antimicrob Agents Chemother 1996;40:2209-11.